Bank Of America Corp Inmune Bio, Inc. Transaction History

Bank Of America Corp

$1.17 Trillion
Q4 2024

A detailed history of Bank Of America Corp transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 30,449 shares of INMB stock, worth $261,556. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,449

Previous 26,434 15.19%

Holding current value

$261,556

Previous $142,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.4 - $6.43 $17,666 - $25,816	4,015 Added 15.19%	30,449 $142,000
Q3 2024 Nov 14, 2024	BUY	$4.86 - $9.86 $71,286 - $144,626	14,668 Added 124.66%	26,434 $142,000
Q2 2024 Aug 14, 2024	BUY	$7.15 - $11.84 $21,435 - $35,496	2,998 Added 34.19%	11,766 $103,000
Q1 2024 May 15, 2024	SELL	$10.53 - $14.01 $56,261 - $74,855	-5,343 Reduced 37.86%	8,768 $103,000
Q4 2023 Feb 14, 2024	BUY	$6.6 - $11.52 $63,624 - $111,052	9,640 Added 215.61%	14,111 $158,000
Q2 2023 Aug 14, 2023	SELL	$6.5 - $10.09 $1,599 - $2,482	-246 Reduced 5.22%	4,471 $40,000
Q1 2023 May 12, 2023	BUY	$6.01 - $10.18 $17,104 - $28,972	2,846 Added 152.11%	4,717 $30,000
Q4 2022 Feb 10, 2023	BUY	$6.13 - $7.96 $79 - $103	13 Added 0.7%	1,871 $11,000
Q2 2022 Aug 12, 2022	SELL	$5.48 - $8.97 $9,316 - $15,249	-1,700 Reduced 47.78%	1,858 $16,000
Q1 2022 May 16, 2022	SELL	$6.42 - $11.39 $1,354 - $2,403	-211 Reduced 5.6%	3,558 $30,000
Q4 2021 Feb 08, 2022	BUY	$9.97 - $20.38 $19,640 - $40,148	1,970 Added 109.51%	3,769 $38,000
Q3 2021 Nov 15, 2021	BUY	$14.13 - $27.85 $1,398 - $2,757	99 Added 5.82%	1,799 $35,000
Q2 2021 Sep 13, 2021	BUY	$9.29 - $19.33 $15,792 - $32,861	1,700 New	1,700 $30,000

Others Institutions Holding INMB

# of Institutions

Shares Held

7.04M

Call Options Held

202K

Put Options Held

42.9K

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $154M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Inmune Bio, Inc. Transaction History